Mereo BioPharma Group plc (NASDAQ: MREO ) and Ultragenyx Pharmaceutical (NASDAQ: RARE ) Inc. announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta is proceeding as planned, with a final analysis expected around the end of the year. According to a press release statement included in a recent SEC filing, the Data Monitoring Committee met and informed Ultragenyx that UX143 demonstrates an acceptable safety profile. The committee recommended that Ultragenyx and Mereo continue the study to the final analysis. The filing also noted that, consistent with the statistical analysis plan, data from the UX143 Cosmic study were not analyzed at this interim timepoint.